255
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Assessing Techniques for Quantifying the Impact of Bias Due to an Unmeasured Confounder: An Applied Example

ORCID Icon, , , , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 627-635 | Published online: 27 Jul 2021

References

  • Lash TL, Fink AK, Fox MP. Unmeasured and unknown confounders. In: Applying Quantitative Bias Analysis to Epidemiologic Data. Springer; 2009:59–78.
  • VanderWeele TJ, Shpitser I. On the definition of a confounder. Ann Stat. 2013;41(1):196–220. doi:10.1214/12-AOS105825544784
  • Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol. 1996;25(6):1107–1116. doi:10.1093/ije/25.6.11079027513
  • Ding P, VanderWeele TJ. Sensitivity analysis without assumptions. Epidemiology. 2016;27(3):368–377. doi:10.1097/EDE.000000000000045726841057
  • Flanders WD, Khoury MJ. Indirect assessment of confounding: graphic description and limits on effect of adjusting for covariates. Epidemiology. 1990;1(3):239–246. doi:10.1097/00001648-199005000-000102081259
  • VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274. doi:10.7326/M16-260728693043
  • Ahern TP, Broe A, Lash TL, et al. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study. J Clin Oncol. 2019;37(21):1800–1809. doi:10.1200/JCO.18.0220230995175
  • Chen FP, Chien MH, Chern IY. Impact of low concentrations of phthalates on the effects of 17beta-estradiol in MCF-7 breast cancer cells. Taiwan J Obstet Gynecol. 2016;55(6):826–834. doi:10.1016/j.tjog.2015.11.00328040128
  • Chen FP, Chien MH. Lower concentrations of phthalates induce proliferation in human breast cancer cells. Climacteric. 2014;17(4):377–384. doi:10.3109/13697137.2013.86572024228746
  • van Meeuwen JA, Korthagen N, de Jong PC, Piersma AH, van den Berg M. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol. 2007;221(3):372–383. doi:10.1016/j.taap.2007.03.01617482226
  • Okubo T, Suzuki T, Yokoyama Y, Kano K, Kano I. Estimation of estrogenic and anti-estrogenic activities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro. Biol Pharm Bull. 2003;26(8):1219–1224. doi:10.1248/bpb.26.121912913283
  • Harris CA, Henttu P, Parker MG, Sumpter JP. The estrogenic activity of phthalate esters in vitro. Environ Health Perspect. 1997;105(8):802–811. doi:10.1289/ehp.971058029347895
  • Hong EJ, Ji YK, Choi KC, Manabe N, Jeung EB. Conflict of estrogenic activity by various phthalates between in vitro and in vivo models related to the expression of Calbindin-D9k. J Reprod Dev. 2005;51(2):253–263. doi:10.1262/jrd.1607515883486
  • Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ Health Perspect. 2004;112(6):751–753. doi:10.1289/ehp.680415121520
  • Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S17908331372058
  • Christiansen P, Ejlertsen B, Jensen M-B, Mouridsen H. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445–449. doi:10.2147/CLEP.S9945727822082
  • Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–256. doi:10.1093/aje/kwp10719494242
  • Kim C, Werther W, Iskander KS, Gruber M, Mezzi K. Demographic and clinical characteristics of multiple myeloma (MM) patients treated with carfilzomib-based regimens in a real world setting. Blood. 2017;130(Supplement 1):5441.
  • Koch HM, Drexler H, Angerer J. An estimation of the daily intake of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population. Int J Hyg Environ Health. 2003;206(2):77–83. doi:10.1078/1438-4639-0020512708228
  • Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the US population. Environ Health Perspect. 2008;117(2):185–189. doi:10.1289/ehp.1176619270786
  • Kelley KE, Hernández-Díaz S, Chaplin EL, Hauser R, Mitchell AA. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect. 2012;120(3):379–384. doi:10.1289/ehp.110399822169271
  • Ording AG, Garne JP, Nyström PMW, et al. Hospital recorded morbidity and breast cancer incidence: a nationwide population-based case-control study. PLoS One. 2012;7(10):e47329–e47329. doi:10.1371/journal.pone.004732923094045
  • Fimea Finnish Medicines Agency. Drug consumption statistics. Consumption 2020; https://www.fimea.fi/web/en/databases_and_registeries/consumption.